ES2636663T3 - Progastrina y patologías hepáticas - Google Patents

Progastrina y patologías hepáticas Download PDF

Info

Publication number
ES2636663T3
ES2636663T3 ES11700114.9T ES11700114T ES2636663T3 ES 2636663 T3 ES2636663 T3 ES 2636663T3 ES 11700114 T ES11700114 T ES 11700114T ES 2636663 T3 ES2636663 T3 ES 2636663T3
Authority
ES
Spain
Prior art keywords
seq
cdr
hvh
hvl
ahx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11700114.9T
Other languages
English (en)
Inventor
Jean-François FLOCH
Leïla HOUHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progastrine et Cancers SARL
Original Assignee
Progastrine et Cancers SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine et Cancers SARL filed Critical Progastrine et Cancers SARL
Application granted granted Critical
Publication of ES2636663T3 publication Critical patent/ES2636663T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Procedimiento para diagnosticar si un paciente presenta múltiples patologías hepáticas, en el que una primera patología hepática ha sido diagnosticada en un paciente, que comprende la etapa de determinación del nivel de progastrina humana (hPG) en una muestra de plasma o suero de dicho paciente, en el que un nivel umbral de progastrina de por lo menos 400 pM indica que dicho paciente probablemente padece por lo menos una patología hepática adicional.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
14
Tabla 3A: Anticuerpos monoclonales anti-PG N-terminales
Inmunógeno
Hibridoma(Nº de depósito) MAb Secuencias CDR murinas Secuencias mVH y mVL Secuencias hVH y hVL (proyectadas)
N1
43B9G11 MAb1
N1
WE5H2G7 MAb2
N2
6B5B11C10 MAb3 VH CDR 1.3 GYIFTSYW (SEC ID NO:1) VH CDR 2.3 FYPGNSDS (SEC ID NO:2)VH CDR 3.3 TRRDSPQY (SEC ID NO:3)VL CDR 1.3 QSIVHSNGNTY (SEC ID NO:4) VL CDR 2.3 KVS (SEC ID NO:5)VL CDR 3.3 FQGSHVPFT (SEC ID NO:6) mVH.3 (SEC ID NO.12) mVL.3 (SEC ID NO: 13) hVH.3 (SEC ID NO:21)hVL.3 (SEC ID NO:22)
N2
20D2C3G2 MAb4 VH CDR 1.4 GYTFSSSW (SEC ID NO:7) VH CDR 2.4 FLPGSGST (SEC ID NO:8)VH CDR 3.4 ATDGNYDWFAY (SEC ID NO:9)VL CDR 1.4 QSLVHSSGVTY (SEC ID NO:10) VL CDR 2.4 KVS (SEC ID NO:5)VL CDR 3.4 SQSTHVPPT (SEC ID NO:11) mVH.4 (SEC ID NO:14) mVL.4 (SEC ID NO: 15) hVH.4 (SEC ID NO:23)hVL.4 (SEC ID NO:24)
N2
1E9A4A4 (I-4376) MAb15
N2
1E9D9B6 MAb16 VH CDR 1.16 GYTFTSYY (SEC ID NO:39) VH CDR 2.16 INPSNGGT (SEC ID NO:43) VH CDR 3.16 TRGGYYPFDY (SEC ID NO:47) VL CDR 1.16 QSLLDSDGKTY (SEC ID NO:50) VL CDR 2.16 LVS (SEC ID NO:53) VL CDR 3.16 WQGTHSPYT (SEC ID NO:57) mVH.16 (SEC ID NO:61) mVL.16 (SEC ID NO:65) hVH.16a (SEC ID NO:84)hVH.16b (SEC ID NO:86)hVH.16c (SEC ID NO:88)hVL.16a (SEC ID NO:85)hVL.16b (SEC ID NO:87)hVL.16c (SEC ID NO:89)
N2
1C8D10F5 MAb17
N2
1A7C3F11 MAb18
N2
1B3B4F11 MAb19 VH CDR 1.19 GYSITSDYA (SEC ID NO:40) VH CDR 2.19 ISFSGYT (SEC ID NO:44) VH CDR 3.19 AREVNYGDSYHFIDY (SEC ID NO:48) VL CDR 1.19 SQHRTYT (SEC ID NO:51) VL CDR 2.19 VKKDGSH (SEC ID NO:54) VL CDR 3.19 GVGDAIKGQSVFV (SEC ID NO:58) mVH.19 (SEC ID NO:62) mVL.19 (SEC ID NO:66) hVH.19a (SEC ID NO:90)hVH.19b (SEC ID NO:92)hVH.19c (SEC ID NO:94)hVL.19a (SEC ID NO.91)hVL.19b (SEC ID NO:93)hVL.19c (SEC ID NO:95)
N2
1C11F5E8 MAb20
Inmunógeno N1 = SWKPRSQQPDAPLG-Ahx-Cys-BSA, también representado como (SEC ID NO:25)-Ahx-Cys-BSAInmunógeno N2 = SWKPRSQQPDAPLG-Ahx-Cys-KLH, también representado como (SEC ID NO:25)-Ahx-Cys-KLH
En la tabla 3A, todas las secuencias de aminoácidos se representan utilizando orientación N→C convencional. Para cada inmunógeno, el péptido progastrina se sintetizó conun enlazador C-terminal de un residuo de ácido aminohexanoico (Ahx) seguido de un residuo de cisteína (Cys), que se conjugó después o bien a un vehículo de seroalbúminabovina ("BSA") o bien de hemocianina de lapa californiana ("KLH") por medio de un residuo enlazador de Cys.
imagen13
16
Tabla 3B: Anticuerpos monoclonales anti-PGh C-terminales
Inmunógeno
Hibridoma(Nº de depósito) MAb Secuencias CDR murinas Secuencias mVH y mVL Secuencias hVH y hVL(proyectadas)
C1
1B4A11D11(I-4371) MAb5
C1
1B6A11F2 (I-4372) MAb6
C1
1B11E4B11(I-4373) MAb7
C1
1C10D3B9 MAb8 VH CDR 1.8 GFTFTTYA (SEC ID NO:37) VH CDR 2.8 ISSGGTYT (SEC ID NO:41) VH CDR 3.8ATQGNYSLDF (SEC ID NO:45) VL CDR 1.8KSLRHTKGITF (SEC ID NO:49) VL CDR 2.8 QMS (SEC ID NO:52) VL CDR 3.8 AQNLELPLT (SEC ID NO:55) mVH.8 (SEC ID NO:59) mVL.8 (SEC ID NO:63) hVH.8a (SEC ID NO:75)hVH.8b (SEC ID NO:77)hVH.8c (SEC ID NO:79)hVL.8a (SEC ID NO:76)hVL.8b (SEC ID NO:78)hVL.8c (SEC ID NO:76)
C1
1D8F5B3 MAb9
C1
1E1C7B4 MAb10
C1
2B4C8C8 (I-4374) MAb11
C1
2B11E6G4(I-4375) MAb12
C1
2C6C3C7 MAb13 VH CDR 1.13 GFIFSSYG (SEC ID NO:38) VH CDR 2.13 INTFGDRT (SEC ID NO:42) VH CDR 3.13 ARGTGTY (SEC ID NO:46)VL CDR 1.13QSLLDSDGKTY (SEC ID NO:50) VL CDR 2.13 LVS (SEC ID NO:53) VL CDR 3.13WQGTHFPQT (SEC ID NO:56) mVH.13 (SEC ID NO:60) mVL.13 (SEC ID NO:64) hVH.1 (SEC ID NO:80)hVH.13b (SEC ID NO:82)hVL.13a (SEC ID NO:81)hVL.13b (SEC ID NO:83)
C1
2H9F4B7 MAb14
C2
1F11F5E10 MAb21
C2
1F11F5G9 MAb22
C2
1A11F2C9 MAb23
Inmunógeno C1 = KLH-Cys-Ahx-Ahx-QGPWLEEEEEAYGWMDFGRRSAEDEN, también representado como KLH-Cys-Ahx-Ahx-(SEC ID NO:27)Inmunógeno C2 = DT-Cys-Ahx-Ahx-QGPWLEEEEEAYGWMDFGRRSAEDEN, también representado como DT-Cys-Ahx-Ahx-(SEC ID NO:27)
En la tabla 3B, todas las secuencias de aminoácidos se representan utilizando orientación N→C convencional. Para cada inmunógeno, el péptido progastrina sesintetizó con un enlazador Ahx-Ahx-Cys N-terminal, que se conjugó después o bien con un vehículo de hemocianina de lapa californiana ("KLH") o bien de unatoxina de difteria ("DT") por medio de un residuo enlazador de Cys.
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
    imagen2
ES11700114.9T 2010-01-08 2011-01-07 Progastrina y patologías hepáticas Active ES2636663T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29355710P 2010-01-08 2010-01-08
US293557P 2010-01-08
PCT/EP2011/000047 WO2011083089A1 (en) 2010-01-08 2011-01-07 Progastrin and liver pathologies

Publications (1)

Publication Number Publication Date
ES2636663T3 true ES2636663T3 (es) 2017-10-06

Family

ID=43567758

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11700114.9T Active ES2636663T3 (es) 2010-01-08 2011-01-07 Progastrina y patologías hepáticas

Country Status (15)

Country Link
US (1) US8900817B2 (es)
EP (1) EP2542898B8 (es)
JP (1) JP5543614B2 (es)
KR (2) KR20120102157A (es)
CN (1) CN102947707B (es)
AU (1) AU2011204652B2 (es)
BR (1) BR112012016767A2 (es)
CA (1) CA2786437C (es)
EA (1) EA023653B1 (es)
ES (1) ES2636663T3 (es)
NZ (1) NZ601593A (es)
PL (1) PL2542898T3 (es)
SG (1) SG182332A1 (es)
WO (1) WO2011083089A1 (es)
ZA (1) ZA201205002B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028515B1 (ru) * 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
FR2980196B1 (fr) * 2011-09-16 2013-10-04 Univ Dauvergne Clermont I Principe actif anticancereux issu de guiera senegalensis
AU2017204685B2 (en) 2015-12-31 2022-10-13 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
MA43550A (fr) * 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
BR112018013272A2 (pt) 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer esofágico
CN108780091A (zh) 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
EP3601347B1 (en) 2017-03-30 2021-11-03 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
WO2018178364A1 (en) 2017-03-30 2018-10-04 Progastrine Et Cancers S.À R.L. Compositions and methods for treating lung cancer
TW201940881A (zh) * 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
WO2019166499A1 (en) 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
RU2761729C1 (ru) * 2021-04-26 2021-12-13 Вячеслав Леонидович Коробка Способ оценки риска смерти при циррозе печени

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2384519C (en) 1991-03-04 2006-08-15 Bayer Corporation Automated analyzer
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
DE69935977T2 (de) * 1998-05-15 2008-01-10 Receptor Biologix, Inc., Palo Alto Vorbeugung und Behandlung von Hypergastrinämie
US7668661B2 (en) * 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US7381370B2 (en) 2003-07-18 2008-06-03 Dade Behring Inc. Automated multi-detector analyzer
EP2567974A3 (en) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
ES2727306T3 (es) * 2006-05-22 2019-10-15 Inst Nat Sante Rech Med Inhibidores de progastrina en el tratamiento del cáncer de colon
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
AR078659A1 (es) 2009-10-16 2011-11-23 Biorealites S A Anticuerpos monoclonales contra progastrina humana y sus usos
EA028515B1 (ru) * 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени

Also Published As

Publication number Publication date
CA2786437A1 (en) 2011-07-14
BR112012016767A2 (pt) 2017-09-05
JP5543614B2 (ja) 2014-07-09
EP2542898A1 (en) 2013-01-09
AU2011204652B2 (en) 2014-04-03
EP2542898B8 (en) 2017-08-09
NZ601593A (en) 2014-08-29
JP2013516617A (ja) 2013-05-13
EP2542898B1 (en) 2017-05-03
ZA201205002B (en) 2013-10-30
AU2011204652A1 (en) 2012-07-26
CN102947707B (zh) 2016-06-01
WO2011083089A1 (en) 2011-07-14
KR20120102157A (ko) 2012-09-17
SG182332A1 (en) 2012-08-30
PL2542898T3 (pl) 2017-10-31
US8900817B2 (en) 2014-12-02
CA2786437C (en) 2020-09-01
KR20140132418A (ko) 2014-11-17
EA201200997A1 (ru) 2013-02-28
KR101688106B1 (ko) 2016-12-20
CN102947707A (zh) 2013-02-27
US20110229488A1 (en) 2011-09-22
EA023653B1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
ES2636663T3 (es) Progastrina y patologías hepáticas
TWI836305B (zh) 抗ｇａｒｐ抗體及其製造方法及用途
PE20070183A1 (es) Anticuerpos monoclonales anti-trkb
ES2525704T3 (es) Proteínas de unión a antígenos
ES2542757T3 (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide
AR062065A1 (es) Anticuerpo humanizado
RU2011151069A (ru) Анти-axl антитело
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
NZ581418A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
EP3324996A2 (en) Gdf11 binding proteins and uses thereof
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
RU2014134747A (ru) Гуманизированные антитела, которые распознают альфа-синуклеин
RU2010133547A (ru) Анти-cldn антитела
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
TW200801040A (en) Binding proteins specific for insulin-like growth factors and uses thereof
AR082916A1 (es) Moleculas de union a 4-1bb
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
TW200906856A (en) Anti-Notch1 NRR antibodies and methods using same
PE20110385A1 (es) Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
CN110914304A (zh) Cd96抗体、其抗原结合片段及医药用途
CO6220841A2 (es) Anticuerpos para linfotoxina-alfa